Holen Sie sich die Stockscreener-App
122.06
10.64%
-14.54
Handel nachbörslich:
122.30
0.24
+0.20%
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Palvella launches disease awareness campaign for rare lymphatic condition - Investing.com Nigeria
Quarterly Earnings: Can Palvella Therapeutics Inc lead its sector in growth2026 Price Swings & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Chipmakers Recap: Can Palvella Therapeutics Inc deliver alphaQuarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Palvella Therapeutics stock rating maintained at Buy by Clear Street - Investing.com
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations - Yahoo Finance
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Published on: 2026-03-07 20:09:49 - baoquankhu1.vn
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Blue Owl Capital Holdings LP Reduces Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment - Stocktwits
Aug Closing: Is Palvella Therapeutics Inc stock trending bullishJuly 2025 Final Week & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Royce & Associates LP Decreases Stock Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update - MarketBeat
Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder - MyChesCo
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares - Investing.com Australia
Palvella Therapeutics raises $230M in upsized stock offering By Investing.com - Investing.com Canada
Palvella Therapeutics raises $230M in upsized stock offering - Investing.com Australia
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares By Investing.com - Investing.com Canada
Palvella therapeutics (PVLA) director buys $500k in stock By Investing.com - Investing.com Australia
Palvella therapeutics (PVLA) director buys $500k in stock - Investing.com South Africa
Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares - MarketBeat
Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock - MarketBeat
Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing - marketscreener.com
Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Is Palvella Therapeutics (PVLA) Still Attractive After A 7x One-Year Surge In Price? - simplywall.st
PVLA PE Ratio & Valuation, Is PVLA Overvalued - Intellectia AI
Palvella Therapeutics Announces Underwritten Common Stock Offering - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade - Defense World
PVLA Stock Surges 86% With A 6-day Winning Spree On Phase 3 Win - Trefis
Palvella prices $200M stock offering at $125 per share - Investing.com Australia
Strategic Update: PVLA Surges Amid New Growth Plans - timothysykes.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up After Analyst Upgrade - MarketBeat
Palvella Therapeutics shares rise to three-year high on upsized offering - Investing.com UK
Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge - simplywall.st
What is Lifesci Capital's Estimate for PVLA FY2026 Earnings? - MarketBeat
HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings - MarketBeat
Palvella Therapeutics, Inc. (PVLA) Stock Analysis: A Potential 74% Upside in the Biotech Sector - DirectorsTalk Interviews
Palvella Therapeutics announces pricing of upsized public offering - marketscreener.com
Palvella prices $200M stock offering at $125 per share By Investing.com - Investing.com India
Palvella Therapeutics Announces Upsized Public Offering Pricing for February 2026 - geneonline.com
Palvella Therapeutics Announces Pricing of Upsized Public Offering - Bitget
Palvella Therapeutics Announces Pricing Of Upsized Public Offering - TradingView
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho - MarketBeat
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright - Yahoo Finance
BTIG Research Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $215.00 - MarketBeat
Palvella launches $150M public stock offering By Investing.com - Investing.com India
Chardan Capital Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock Price - Defense World
Palvella launches $150M public stock offering - Investing.com Australia
Palvella Therapeutics Shares Jump as Phase 3 SELVA Trial Hits Primary Endpoint for QTORIN Rapamycin - MarketBeat
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):